

Table S1. Search strategy for studies assessing the effect of fructose and its epimers (allulose, tagatose and sorbose) on markers of long-term glycemic control

Database	Search Period	Search Terms
MEDLINE	1946 to April 18, 2018	<ol style="list-style-type: none"> 1. exp Fructose/ 2. psicose.mp. 3. allulose.mp. 4. tagatose.mp. 5. sorbose.mp. 6. 1 or 2 or 3 or 4 or 5 7. exp Glucose/ 8. glycaemic.mp. 9. glyceemic.mp. 10. glycaemia.mp. 11. glycemia.mp. 12. exp Insulin/ 13. exp Glucose Tolerance Test/ 14. OGTT.mp. 15. exp Hemoglobin A, Glycosylated/ 16. HbA1c.mp. 17. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 18. 6 and 17 19. limit 18 to animals 20. 18 not 19 21. clinical trial.mp. 22. clinical trial.pt. 23. random:.mp. 24. tu.xs. 25. 21 or 22 or 23 or 24 26. 20 and 25
EMBASE	1946 to April 18, 2018	<ol style="list-style-type: none"> 1. exp fructose/ 2. psicose.mp. 3. allulose.mp. 4. tagatose.mp. 5. sorbose.mp. 6. 1 or 2 or 3 or 4 or 5 7. exp glucose/ 8. glycaemic.mp. 9. glyceemic.mp. 10. glycaemia.mp. 11. glycemia.mp. 12. exp insulin/ 13. exp oral glucose tolerance test/ 14. OGTT.mp. 15. exp hemoglobin A1c/ 16. HbA1c.mp. 17. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 18. 6 and 17 19. limit 18 to animals 20. 18 not 19 21. random:.tw. 22. clinical trial:.mp. 23. exp health care quality/

		<ul style="list-style-type: none"> 24. 21 or 22 or 23 25. 20 and 24
Cochrane Central Register of Controlled Trials	1946 to April 18, 2018	<ul style="list-style-type: none"> 1. Fructose/ 2. psicose.mp. 3. tagatose.mp. 4. 1 or 2 or 3 5. Glucose/ 6. glycaemic.mp. 7. glycemic.mp. 8. glycaemia.mp. 9. glycemia.mp. 10. Insulin/ 11. exp Glucose Tolerance Test/ 12. OGTT.mp. 13. exp Hemoglobin A, Glycosylated/ 14. HbA1c.mp. 15. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 16. 4 and 15

Table S2. Select sensitivity analyses in which the systematic removal of an individual trial altered the effect estimate or the evidence for heterogeneity

Outcome	Removal of	MD [95% CI], P-value I ² , P-value
ALLULOSE		
Fasting glucose, mmol/l	Hayashi et al.	-0.28 [-0.52, -0.04], p=0.02 I ² =0%, P _Q =0.57
TAGATOSE		
Fasting glucose, mmol/l	Ensor et al.	-0.12 [-0.61, 0.37], p=0.63 I ² =NA P _Q =NA

Table S3. Sensitivity analyses using correlation coefficients of 0.25 and 0.75 for crossover trials

Outcome (No. crossover trials/total trials)	MD [95% CI], P-value I ² , P-value	
	Correlation coefficient of 0.25	Correlation coefficient of 0.75
FRUCTOSE		
HbA _{1c} , % (3/7)	-0.40 [-0.67, -0.13], p=0.003 I ² = 0%, P _Q =0.57	-0.34 [-0.62, -0.06], p=0.02 I ² = 33%, P _Q =0.18
Fasting glucose, mmol/L (7/12)	-0.14 [-0.25, -0.03], p=0.01 I ² = 30%, P _Q =0.16	-0.12 [-0.27, 0.02], p=0.10 I ² = 48%, P _Q =0.04
Fasting insulin, pmol/L (6/10)	3.78 [-3.46, 11.02], p=0.31 I ² = 0%, P _Q =0.64	-1.50 [-8.83, 5.82], p=0.69 I ² = 13%, P _Q =0.33
TAGATOSE		
Fasting glucose, mmol/L (1/2)	-0.33 [-0.60, -0.05], p=0.02 I ² = 0%, P _Q =0.46	-0.27 [-0.50, -0.03], p=0.03 I ² = 14%, P _Q =0.28
Fasting insulin, pmol/L (2/3)	-1.12 [-6.86, 4.63], p=0.70 I ² = 36%, P _Q =0.21	-2.42 [-7.00, 2.15], p=0.30 I ² = 70%, P _Q =0.04

Table S4. GRADE assessment

Grading of Recommendations, Assessment, Development and Evaluation (GRADE)							Quality
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	
HbA_{1c} in FRUCTOSE trials							
7	randomized trials	not serious	not serious	serious ¹	serious ²	none ¹⁵	⊕⊕○○ LOW
Fasting glucose in FRUCTOSE trials							
12	randomized trials	not serious	not serious	serious ³	serious ⁴	none	⊕⊕○○ LOW
Fasting insulin in FRUCTOSE trials							
10	randomized trials	not serious	not serious	serious ⁵	serious ⁶	none	⊕⊕○○ LOW
HbA_{1c} in ALLULOSE trials							
2	randomized trials	not serious	not serious	serious ⁷	serious ⁸	none ¹⁵	⊕⊕○○ LOW
Fasting glucose in ALLULOSE trials							
2	randomized trials	not serious	not serious	serious ⁷	serious ⁹	none ¹⁵	⊕⊕○○ LOW
Fasting insulin in ALLULOSE trials							
2	randomized trials	not serious	not serious	serious ⁷	serious ¹⁰	none ¹⁵	⊕⊕○○ LOW
HbA_{1c} in TAGATOSE trial							
1	randomized trials	not serious	not serious	not serious ¹¹	serious ¹²	none ¹⁵	⊕⊕⊕○ MODERATE
Fasting glucose in TAGATOSE trials							
2	randomized and non-randomized trials	not serious	not serious	not serious ¹¹	serious ¹³	none ¹⁵	⊕⊕⊕○ MODERATE
Fasting insulin in TAGATOSE trials							
3	randomized and non-randomized trials	not serious	serious	not serious ¹¹	serious ¹⁴	none ¹⁵	⊕⊕⊕○ MODERATE

¹ Serious indirectness for the effect of small doses of fructose on HbA_{1c}, as the median follow-up duration was relatively short (2.5 weeks) Only 3/7 trials had a follow-up duration of ≥ 8 -weeks.

² Serious imprecision for the effect of small doses of fructose on HbA_{1c}, as the 95% CIs (-0.64% to -0.13%) overlap the minimally important difference for clinical benefit (0.3%)

³ Serious indirectness for the effect of small doses of fructose on fasting glucose, as the median follow-up duration was relatively short (2 weeks).

⁴ Serious imprecision for the effect of small doses of fructose on fasting glucose, as the 95% CIs (-0.24 mmol/l to -0.03 mmol/l) overlap the minimally important difference for clinical benefit (0.5 mmol/l)

⁵ Serious indirectness for the effect of small doses of fructose on fasting insulin, as the median follow-up duration was relatively short (2 weeks).

⁶ Serious imprecision for the effect of small doses of fructose on fasting insulin, as the 95% CIs (-4.19 pmol/l to 9.62 pmol/l) overlap the minimally important difference for clinical benefit (5 pmol/l)

⁷ Serious indirectness for the effect of small doses of allulose on HbA_{1c}, fasting glucose and fasting insulin, as the study setting was limited to Asia (Japan and Korea) which may affect the generalizability of the results

⁸ Serious imprecision for the effect of small doses of allulose on HbA_{1c}, as the 95% CIs (-0.03% to 0.07%) overlap the minimally important difference for clinical benefit (0.3%)

⁹ Serious imprecision for the effect of small doses of allulose on fasting glucose, as the 95% CIs (-0.35 mmol/l to 0.00 mmol/l) overlap the minimally important difference for clinical benefit (0.5 mmol/l)

¹⁰ Serious imprecision for the effect of small doses of allulose on fasting insulin, as the 95% CIs (-2.17 pmol/l to 0.79 pmol/l) overlap the minimally important difference for clinical benefit (5 pmol/l)

¹¹ No serious indirectness of the effect of small doses of tagatose on HbA_{1c}, fasting glucose, and fasting insulin, as 356 – 378 participants were included in the analysis even though 1 – 3 trials were available. Trials were of sufficient length and assessed the effect of small doses of tagatose in a large population of interest (i.e. type 2 diabetes). The one multi-center trial (USA & India) studying 356 participants with type 2 diabetes had a follow-up duration of 40 weeks.

¹² Serious imprecision for the effect of small doses of tagatose on HbA_{1c}, as the 95% CIs (-0.34% to -0.06%) overlap the minimally important difference for clinical benefit (0.3%)

¹³ Serious imprecision for the effect of small doses of tagatose on fasting glucose, as the 95% CIs (-0.57 mmol/l to 0.04 mmol/l) overlap the minimally important difference for clinical benefit (0.5 mmol/l)

¹⁴ Serious imprecision for the effect of small doses of tagatose on fasting insulin, as the 95% CIs (-6.95 pmol/l to 3.77 pmol/l) overlap the minimally important difference for clinical benefit (5 pmol/l)

¹⁵ Not able to assess publication bias as <10 trials were available






Figure S1. Risk of bias summary of controlled feeding trials assessing the effect of small doses of fructose (top), allulose (middle) and tagatose (bottom) on markers of glycemic control. Colored bars represent the proportion of studies assessed as low (green), unclear (yellow) and high (red) risk of bias for the 6 domains of bias above according to criteria set by the Cochrane Risk of Bias tool.




Figure S2. Forest plot of the effect of small doses (≤ 50 g/day) of fructose on HbA_{1c}. Pooled effect estimates for the overall effect is represented by the diamond. Data are expressed as mean differences (MDs) with 95% confidence intervals (CIs), using the generic inverse variance method with random effects models. Paired analyses were applied to all crossover trials. Values are between-treatment end differences for six of the seven trials (Rizkalla *et al.* (Expt 1) [43], Paganus *et al.* (control) [45], Paganus *et al.* (guar) [45], Grigoresco *et al.* [46], Vaisman *et al.* [49], Blayo *et al.* [47]), as change-from-baseline data were not available. Inter-study heterogeneity was tested by the Cochran Q-statistic at a significance level of $p < 0.10$ and quantified by I^2 , levels $\leq 50\%$ represent moderate heterogeneity, $\geq 50\%$ representing substantial heterogeneity, and $\geq 75\%$ representing considerable heterogeneity.




Figure S3. Forest plot of the effect of small doses (≤ 50 g/day) of fructose on fasting glucose. Pooled effect estimates for the overall effect is represented by the diamond. Data are expressed as mean differences (MDs) with 95% confidence intervals (CIs), using the generic inverse variance method with random effects models. Paired analyses were applied to all crossover trials. Values are between-treatment end differences for all trials, as change-from-baseline data were not available. Inter-study heterogeneity was tested by the Cochran Q-statistic at a significance level of $p < 0.10$ and quantified by I^2 , levels $\leq 50\%$ represent moderate heterogeneity, $\geq 50\%$ representing substantial heterogeneity, and $\geq 75\%$ representing considerable heterogeneity.




Figure S4. Forest plot of the effect of small doses (≤ 50 g/day) fructose on fasting insulin. Pooled effect estimates for the overall effect is represented by the diamond. Data are expressed as mean differences (MDs) with 95% confidence intervals (CIs), using the generic inverse variance method with random effects models. Paired analyses were applied to all crossover trials. Values are between-treatment end differences for all trials, as change-from-baseline data were not available. Inter-study heterogeneity was tested by the Cochran Q-statistic at a significance level of $p < 0.10$ and quantified by I^2 , levels $\leq 50\%$ represent moderate heterogeneity, $\geq 50\%$ representing substantial heterogeneity, and $\geq 75\%$ representing considerable heterogeneity.




Figure S5. Forest plot of the effect of small doses (≤ 50 g/day) of allulose on HbA_{1c}. Pooled effect estimate for the overall effect is represented by the diamond. Data are expressed as mean differences (MDs) with 95% confidence intervals (CIs), using the generic inverse variance method with fixed effects models. Paired analyses were applied to all crossover trials. Values are between-treatment end differences for Hayashi *et al.* [11], as change-from-baseline data were not available. Inter-study heterogeneity was tested by the Cochran Q-statistic at a significance level of $p < 0.10$ and quantified by I², levels $\leq 50\%$ represent moderate heterogeneity, $\geq 50\%$ representing substantial heterogeneity, and $\geq 75\%$ representing considerable heterogeneity




Figure S6. Forest plot of the effect of small doses (≤ 50 g/day) of allulose on fasting glucose. Pooled effect estimate for the overall effect is represented by the diamond. Data are expressed as mean differences (MDs) with 95% confidence intervals (CIs), using the generic inverse variance method with fixed effects models. Paired analyses were applied to all crossover trials. Values are between-treatment end differences for Hayashi *et al.* [11], as change-from-baseline data were not available. Inter-study heterogeneity was tested by the Cochran Q-statistic at a significance level of $p < 0.10$ and quantified by I^2 , levels $\leq 50\%$ represent moderate heterogeneity, $\geq 50\%$ representing substantial heterogeneity, and $\geq 75\%$ representing considerable heterogeneity




Figure S7. Forest plot of the effect of small doses (≤ 50 g/day) of allulose on fasting insulin. Pooled effect estimate for the overall effect is represented by the diamond. Data are expressed as mean differences (MDs) with 95% confidence intervals (CIs), using the generic inverse variance method with fixed effects models. Paired analyses were applied to all crossover trials. Values are between-treatment end differences for Hayashi *et al.* [11], as change-from-baseline data were not available. Inter-study heterogeneity was tested by the Cochran Q-statistic at a significance level of $p < 0.10$ and quantified by I^2 , levels $\leq 50\%$ represent moderate heterogeneity, $\geq 50\%$ representing substantial heterogeneity, and $\geq 75\%$ representing considerable heterogeneity




Figure S8. Forest plot of the effect of small doses (≤ 50 g/day) of tagatose on HbA_{1c}. Pooled effect estimate for the overall effect is represented by the diamond. Data are expressed as mean differences (MDs) with 95% confidence intervals (CIs), using the generic inverse variance method with fixed effects models. Paired analyses were applied to all crossover trials. Values are between-treatment end differences, as change-from-baseline data were not available. Inter-study heterogeneity was tested by the Cochran Q-statistic at a significance level of $p < 0.10$ and quantified by I^2 , levels $\leq 50\%$ represent moderate heterogeneity, $\geq 50\%$ representing substantial heterogeneity, and $\geq 75\%$ representing considerable heterogeneity




Figure S9. Forest plot of the effect of small doses (≤ 50 g/day) of tagatose on fasting glucose. Pooled effect estimate for the overall effect is represented by the diamond. Data are expressed as mean differences (MDs) with 95% confidence intervals (CIs), using the generic inverse variance method with fixed effects models. Paired analyses were applied to all crossover trials. Values are between-treatment end differences, as change-from-baseline data were not available. Inter-study heterogeneity was tested by the Cochran Q-statistic at a significance level of $p < 0.10$ and quantified by I^2 , levels $\leq 50\%$ represent moderate heterogeneity, $\geq 50\%$ representing substantial heterogeneity, and $\geq 75\%$ representing considerable heterogeneity




Figure S10. Forest plot of the effect of small doses (≤ 50 g/day) of tagatose on fasting insulin. Pooled effect estimate for the overall effect is represented by the diamond. Data are expressed as mean differences (MDs) with 95% confidence intervals (CIs), using the generic inverse variance method with fixed effects models. Paired analyses were applied to all crossover trials. Values are between-treatment end differences for two of the three trials (Buemann *et al.* [55], Boesch *et al.* [56]), as change-from-baseline data were not available. Inter-study heterogeneity was tested by the Cochran Q-statistic at a significance level of $p < 0.10$ and quantified by I^2 , levels $\leq 50\%$ represent moderate heterogeneity, $\geq 50\%$ representing substantial heterogeneity, and $\geq 75\%$ representing considerable heterogeneity




Figure S11. Forest plot of subgroup analyses investigating the effect of small doses of fructose on fasting glucose. Subgroups include age, comparator, dose, fructose form, design, duration and energy balance. Data are represented as MD with 95% CIs. Differences between subgroups were tested using meta-regression and the significance level was reported as a p-value, where $p < 0.05$ is considered significant. The residual I^2 value indicates heterogeneity unexplained by the subgroup.




Figure S12. Forest plot of subgroup analyses investigating the effect of small doses of fructose on fasting glucose. Subgroups include random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selecting outcome reporting. Data are represented as MD with 95% CIs. Differences between subgroups were tested using meta-regression and the significance level was reported as a p-value, where $p < 0.05$ is considered significant. The residual I^2 value indicates heterogeneity unexplained by the subgroup.




Figure S13. Forest plot of subgroup analyses investigating the effect of small doses of fructose on fasting insulin. Subgroups include age, comparator, dose, fructose form, design, duration and energy balance. Data are represented as MD with 95% CIs. Differences between subgroups were tested using meta-regression and the significance level was reported as a p-value, where $p < 0.05$ is considered significant. The residual I^2 value indicates heterogeneity unexplained by the subgroup.




Figure S14. Forest plot of subgroup analyses investigating the effect of small doses of fructose on fasting insulin. Subgroups include age, comparator, dose, fructose form, design, duration and energy balance. Data are represented as MD with 95% CIs. Differences between subgroups were tested using meta-regression and the significance level was reported as a p-value, where p<0.05 is considered significant. The residual I² value indicates heterogeneity unexplained by the subgroup.




Figure S15. Publication bias funnel plots for the effect of small doses ($\leq 50\text{g/d}$) of fructose on fasting glucose (top) and fasting insulin (bottom). The solid line represents the pooled effect estimate expressed as the mean difference (MD). The dashed line represents pseudo-95% confidence intervals and the circles represent effect estimates for each included study. P-values were derived from quantitative assessment of publication bias by Egger's and Begg's test set at a significance level of $p < 0.05$